Pharmaceutical company in
Allschwil

52 companies in Pharmaceutical company based in Allschwil — name and year of registration from the commercial register.

Companies

50 of 52 companies

Abbott Products Operations AG

Since 2000 · 21–50 empl.5.0(5)

Abbott Products Operations AG is a healthcare company that develops, manufactures and supplies products and therapies in diabetes management, diagnostics, medical nutrition, vascular therapies and neuromodulation. The website specifically lists diabetes-care solutions such as the FreeStyle Libre blood glucose monitoring system.

Pharmaceutical companyDiabetes treatmentDiagnosticsNutrition

Basilea Pharmaceutica International AG, Allschwil

Since 2008 · 101–500 empl.4.5(2)

Basilea Pharmaceutica International AG, Allschwil is a biopharmaceutical company that discovers, develops and commercializes medicines for severe bacterial and fungal infections. Its portfolio includes marketed anti-infective medicines as well as drug candidates in clinical and preclinical development.

Pharmaceutical companyDevelopment and commercialization of anti-infectivesAntimycoticsAntibiotics

Idorsia Pharmaceuticals Ltd

Since 2017 · 500+ empl.3.9(19)

Idorsia Pharmaceuticals Ltd discovers, develops, and commercializes medicines. Its activities include drug research and clinical development across therapeutic areas such as central nervous system, cardiovascular and immunological disorders, and rare diseases.

Pharmaceutical companyDiscovery, development and marketing of innovative medicinesCompassionate Use ProgramTransparency and disclosure reports

Basilea Pharmaceutica AG, Allschwil

Since 2002 · 101–500 empl.4.5(2)

Basilea Pharmaceutica AG, Allschwil develops and commercializes medicines for serious bacterial and fungal infections. The biopharmaceutical company markets Cresemba and Zevtera and develops additional anti-infective drug candidates.

Pharmaceutical companyDevelopment and commercialization of anti-infectivesAntifungal CresembaAntibiotic Zevtera

Merz Pharma (Schweiz) AG

Since 1977 · 51–100 empl.

The core activity of Merz Therapeutics is the development, manufacture and marketing of pharmaceuticals, particularly in the fields of neurology, hepatology and dermatology. The company focuses on researching and developing innovative therapies to improve the quality of life for patients.

Pharmaceutical companySpecialty NeurologyHepatologyDermatology

Pharmatrans Sanaq AG

Since 1982 · 11–20 empl.

Pharmatrans Sanaq AG specializes in excipients and active ingredients for the pharmaceutical industry. It supplies products and customized solutions, and provides services including sourcing, packaging, storage and distribution.

Research instituteExcipients and active ingredientsBindersHigh Performance API

Andreabal AG

Since 1988 · 11–20 empl.

The core activity of Andreabal AG is the development, manufacture and distribution of products for women before, during and after pregnancy, including pregnancy preparation, breastfeeding and menopause, as well as vitamins, iron deficiency and skin and nail care products.

Pharmaceutical companyProducts for pregnancy & breastfeedingProducts and information on vitamins & ironProducts and information on menopause

Abbott Laboratories GmbH

Since 1989 · 51–100 empl.

Abbott Laboratories GmbH represents the Abbott group and provides services for the sale and marketing of its products. Its areas of activity in Switzerland include pharmaceuticals, diagnostics, diabetes care, medical nutrition, and cardiovascular therapies.

Pharmaceutical companyPharmaceutical products

Actelion Pharmaceuticals Ltd

Since 1997 · 21–50 empl.

Actelion Pharmaceuticals Ltd is a pharmaceutical company focused on the research, development, and marketing of medicines. The website presents Johnson & Johnson Innovative Medicine’s therapeutic areas, including oncology, immunology, neuroscience, and cardiopulmonary care.

Research instituteMedicines and therapiesClinical trialsPatient Resources

Xenometrix AG

Since 2005 · 1–10 empl.

Xenometrix AG develops and supplies bioassay kits and components, particularly for miniaturized Ames tests and the detection of endocrine-active substances. It also provides analytical services for mutagenicity, genotoxicity, endocrine activity and dermal permeation.

Testing and inspection bodyAmes Test KitsPreclinical Service AnalyticsMiniaturized Ames Test

T3 Pharmaceuticals AG

Since 2015 · 11–20 empl.

The core activity of T3 Pharmaceuticals AG is the development of anti-cancer drugs, particularly through the research and development of innovative therapeutics based on microbial pathogenesis and immunotherapy. The company focuses on the discovery and development of new active substances (NCEs) and the clinical development of targeted therapeutics, especially in the fields of oncology and hematology.

Pharmaceutical companyCancer immunotherapy platform with live bacteriaOncology drug-development pipeline

acovos AG

Since 2017 · 1–10 empl.

acovos AG supplies human tissue samples for medical research and the development of drugs and diagnostics. Its products include FFPE tissue samples, matched normal and tumour tissue pairs, and samples pre-tested for specific antibodies.

Pharmaceutical companyHuman FFPE tissue samplesMatched FFPE tissue pairsAntibody-tested FFPE tissues

CAPTOR THERAPEUTICS GmbH

Since 2018 · 11–20 empl.

CAPTOR THERAPEUTICS GmbH is a biopharmaceutical company researching and developing medicines using targeted protein degradation. Its drug discovery programmes include targets for cancer and autoimmune diseases.

Pharmaceutical companyTargeted Protein Degradation (TPD)Optigrade™ PlatformEarly drug development

AlphaMol Science AG

Since 2019 · 1–10 empl.

AlphaMol Science AG is a biotechnology company developing therapeutics targeting G protein-coupled receptors (GPCRs). Its discovery platform combines computational drug design and artificial intelligence with structural biology, medicinal chemistry and experimental pharmacology, with programs in immunology, metabolic disease and pain.

Pharmaceutical companyActive ingredient research and active ingredient designGPCR research and GPCR biotestingMembrane protein structure determination

Alloy Therapeutics (Switzerland) AG

Since 2019 · 21–50 empl.

Alloy Therapeutics (Switzerland) AG develops and provides technologies and services for drug discovery and development. Its activities focus on antibodies and multispecifics, TCR mimics, genetic medicines, pharmacology, and AI/ML-enabled platforms.

Medical technology manufacturerAntibody and Multispecific DiscoveryTCR Mimic Antibody DiscoveryGenetic Medicines Development

Neurocrine Switzerland GmbH

Since 2023 · 1–10 empl.

Neurocrine Switzerland GmbH conducts research and development of treatments for neurological, neuroendocrine and neuropsychiatric disorders. The organisation’s portfolio includes approved medicines for conditions such as tardive dyskinesia, chorea associated with Huntington’s disease, congenital adrenal hyperplasia, endometriosis and uterine fibroids, and it maintains a pipeline with compounds in mid‑to‑late stage clinical development.

Pharmaceutical companyMedicinesResearch and Development of Drug CandidatesClinical Trials

Aschem GmbH

Since 2018 · 1–10 empl.

Aschem GmbH is a fine chemicals company that designs, synthesizes, produces and commercializes building blocks for drug discovery and the pharmaceutical industry. Its services also include custom synthesis, work with active pharmaceutical ingredients, and nanomaterials and drug formulation.

Pharmaceutical companyChemical Synthesis and ServicesCompoundsSpecialty Chemical Reagents and Building Blocks

InCephalo AG

Since 2021 · 1–10 empl.

InCephalo AG develops biologic medicines for diseases of the central nervous system. Its focus is compartment-locked cytokine therapies that act locally, initially for glioblastoma.

Research instituteC-Lock™ PlatformC-Locked BiologicsGlioblastoma Therapy (InC01)

Blue Wave Therapeutics GmbH

Since 2021 · 11–20 empl.

The core activity of Blue Wave Therapeutics GmbH is the development of targeted radionuclide therapies for the treatment of solid tumors.

Pharmaceutical companyTargeted radionuclide therapies for solid tumorsARAspheresRadioactive biopolymer technology platform

Bright Peak Therapeutics AG

Since 2017 · 51–100 empl.5.0(1)

Bright Peak Therapeutics AG is a biotechnology company developing multifunctional precision immunotherapies for cancer. Its work includes multifunctional PD-1 inhibitors that combine novel and validated mechanisms.

Research instituteDevelopment of multifunctional precision immunotherapiesProtein engineering

Merz Aesthetics (Schweiz) AG

Since 2023 · 1–10 empl.4.4(7)

Merz Aesthetics (Schweiz) AG develops and markets medicinal products and patient-focused services in therapeutic areas such as neurology, dermatology and health. Its activities include therapies and supporting services for patients.

Pharmaceutical companyNeurology Products

MiHKAL GmbH

Since 2021 · 1–10 empl.

MiHKAL GmbH conducts pharmaceutical research and development, focusing on drug candidates for mental health conditions. It is developing prodrugs for post-traumatic stress disorder and offers custom synthesis, small-molecule analytics and consulting services.

Pharmaceutical companyResearch and Development of Drug CandidatesCRO Services

Alentis Therapeutics AG

Since 2019 · 21–50 empl.5.0(1)

Alentis Therapeutics AG is a biotechnology company developing antibodies and antibody-drug conjugates targeting Claudin-1. Its clinical pipeline includes drug candidates for Claudin-1-positive solid tumors and organ fibrosis.

Pharmaceutical companyAnti-Claudin-1 antibody-drug conjugates (ALE.P02, ALE.P03)Lixudebart (ALE.F02) for organ fibrosis

Phialogics AG

Since 2022 · 1–10 empl.

Research institute

Palto Therapeutics AG

Since 2020 · 1–10 empl.

Palto Therapeutics AG develops novel formulations for biological drugs, focusing on oligonucleotide-based therapeutics such as siRNAs to enable targeted cellular uptake and cytoplasmic activation. The company designs proprietary formulation and delivery strategies to address in vivo stability and achieve tissue- or cell-type-specific distribution.

Pharmaceutical companyDevelopment of formulations for biological medicinesDevelopment of oligonucleotide therapeuticsDevelopment of active ingredient delivery strategies

Preclina Europe GmbH

Since 2024 · 1–10 empl.

Preclina Europe GmbH is a non-clinical CRO providing an integrated drug-discovery platform focused on immunology and inflammatory disorders. Services listed on the website include cell-based assays using patient-derived cells, histopathology services, and PK/ADME/toxicology testing.

Pharmaceutical companyImmunology and Inflammation ResearchCell-Based AssayHistopathology Service

Ilonov Therapeutics SA

Since 2025 · 1–10 empl.

Ilonov Therapeutics SA is a preclinical-stage biopharmaceutical company developing biotherapies for diabetes and metabolic diseases. Its research uses myokines from the muscle secretome, with development programs addressing type 1 and type 2 diabetes.

Pharmaceutical companyDevelopment of biotherapies against diabetesTherapeutic candidate ILV-001 for type 1 diabetesTherapeutic candidate ILV-001 for type 2 diabetes

Nanolynx Biologics AG

Since 2025 · 1–10 empl.

Nanolynx Biologics AG develops conditionally active nanobody-drug conjugates for hard-to-treat solid tumors. Its IntelliBody platform uses generative AI to engineer nanobodies that activate in the acidic tumor environment.

Research instituteTumor-activated Nanobody TherapeuticsIntelliBody™ PlatformBiologics Development Partnerships

Gubra GmbH

Since 2026 · 1–10 empl.

Gubra GmbH is a biotechnology company operating through Biotech, CRO services and Ventures. It develops peptide-based drug candidates and provides preclinical research and development services across areas such as obesity, liver, kidney, lung and metabolic diseases.

Research institutePreclinical CRO ServicesPreclinical Studies by Disease AreaPreclinical Imaging (3D Imaging)

GlioCART GmbH

Since 2025 · 1–10 empl.

GlioCART GmbH develops CAR-T cell therapies for glioblastoma. Its dual-action approach targets tumor cells and the immunosuppressive tumor microenvironment, including through EGFRvIII recognition and reprogramming tumor-associated macrophages.

Research instituteCAR-T Therapy for GlioblastomaPipeline of Next-Generation CAR-T Therapies

Hemastatx GmbH

Since 2025 · 1–10 empl.

Hemastatx GmbH develops antibody therapies for severe bleeding disorders. Its HMX-001 development program is a monoclonal antibody targeting ADAMTS13, intended to prevent bleeding in von Willebrand factor-related disorders.

Pharmaceutical companyHMX-001 antibody therapy

Cancentus GmbH

Since 2026 · 1–10 empl.

Cancentus GmbH develops cancer therapies that target DNA replication stress in cancer cells. Its programs include novel payloads for antibody-drug conjugates, a helicase inhibitor and drug combinations; the company also offers AI-driven compound screening and lead optimization.

Research institute

Immuna Therapeutics AG

Since 2025 · 1–10 empl.

Immuna Therapeutics AG develops cell and gene therapies, with a focus on CAR-T and gene therapy platforms for blood cancers and other indications. The company supports hospitals and health systems with decentralized GMP manufacturing, regulatory support, and commercialization.

Research instituteCAR-T Cell TherapyDecentralized GMP ManufacturingRegulatory and Compliance Support

No score yet

BIIE AI Initiative AG

Since 2025 · 1–10 empl.

BIIE AI Initiative AG is the AI initiative of the Botnar Institute of Immune Engineering (BIIE). The website mainly provides privacy policy information and a contact/newsletter form; it contains little detail about specific products or services.

Research instituteAI Research Initiative for Immune Engineering

No score yet PA

PharmaBiome AG

Since 2020 · 1–10 empl.

Pharmaceutical company

No score yet EB

Elaaj Bio AG

Since 2021 · 1–10 empl.

Pharmaceutical company

No score yet ET

Engimmune Therapeutics AG

Since 2021 · 1–10 empl.